Navigation Links
Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinson's Disease
Date:4/20/2012

KIRKLAND, Wash., April 20, 2012 /PRNewswire/ -- A recent clinical trial conducted at Evergreen Healthcare shows that a new form of a common drug used to treat Parkinson's Disease greatly improves the quality of life for patients and reduces the affects of symptoms such as tremors, slowness, stiffness and difficulty walking.

Evergreen was the only site in the Pacific Northwest to hold the trial, which was led by Dr. C. Warren Olanow, a Fellow of the American Academy of Neurology and Professor of Neurology and Neuroscience at the Mount Sinai School of Medicine in New York.

The trial tested standard oral dosages of a Parkinson's drug against the newer levodopa-carbidopa intestinal gel (LCIG) and found that the intestinal treatments gave patients an average of two extra hours per day of reduced symptoms and improved movement.

"We have been involved in the trials since 2008," said Dr. Alida Griffith, principal investigator for the trial at Evergreen's Booth Gardner Parkinson's Care Center. "Levodopa is the 'gold standard' treatment for Parkinson's disease."

The intestinal gel contains levodopa and carbidopa, two drugs commonly prescribed for Parkinson's, and is infused through a portable pump connected to a tube implanted in the intestine.

In the three-month, double-blind trial, 71 participants were randomized to receive either the continuous infusion of LCIG and dummy pills or a dummy intestinal gel and pills that contained levodopa and carbidopa. At the start of the study, the average person had Parkinson's disease for about 11 years and experienced 6.6 hours of symptomatic behavior per day. A total of 93 percent of participants completed the study.

The results of the study are set to be presented as part of the Emerging Science program (formerly known as Late-Breaking Science) at the American Academy of Neurology's 64th Annual Meeting in New Orleans from April 21 to April 28, 2012.

The study was supported by Abbott.

Learn more about Parkinson's disease at http://www.aan.com/patients.

To learn more about the Evergreen Neuroscience Institute, visit www.evergreenhealthcare.org/parkinsons or call the Evergreen Healthline 425.899.3000. 

Evergreen Healthcare, a public hospital district and community-based health care organization established in 1972, offers a breadth of services and programs that is among the most comprehensive in the region. More than 950 physicians provide clinical excellence within more than 80 specialties, including  cardiac, oncology, surgical care, orthopedics, a Neuroscience Institute, Women's and Children's services, hospice care, pulmonary care, a Sleep Disorders Center and Home Health services care.  Evergreen serves more than 400,000 residents in its primary service area of northern King and southern Snohomish counties with Evergreen Medical Group, a network of primary and urgent care practices, and Evergreen Hospital Medical Center, its main hospital campus in Kirkland, Wash. Evergreen also provides emergency care at two sites; its main hospital campus and the Evergreen Redmond Medical Center.  In addition to clinical care, Evergreen offers extensive community health outreach and education programs, anchored by Evergreen Healthline, a 24/7 nurse consultation service. For more information, visit www.evergreenhealthcare.org.

The American Academy of Neurology, an association of more than 25,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as stroke, Alzheimer's disease, epilepsy, Parkinson's disease and multiple sclerosis. For more information about the American Academy of Neurology, visit http://www.aan.com or find us on Facebook, Twitter, Google+ and YouTube.

Media Contacts:

Ken LeBlond, kaleblond@evergreenhealthcare.org, (425) 899-1886

Rachel Seroka, rseroka@aan.com, (651) 695-2738

Angela Babb, APR, ababb@aan.com, (651) 695-2789

AAN Press Room (April 22–27): (504) 670-4511


'/>"/>
SOURCE Evergreen Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Webcast Alert: Isis Pharmaceuticals Holds Webcast to Discuss Clinical Development Plans for ISIS-APOCIIIRx
2. Global BioClinical Launches New Website
3. Frost & Sullivan: Industry Push toward Quantitative Imaging Positions Computer Aided Detection and Diagnosis Adequately for Renewed Clinical Expansion
4. R&D Trends: Depression - Clinical attrition driven by mature market conditions
5. New Studies Demonstrate Clinical Utility and Validity of CancerType ID® Molecular Classifier
6. iBio Announces Successful Completion of H1N1 Influenza Vaccine Phase 1 Clinical Trial
7. Sysmex America Achieves Clinical Laboratory Connectivity Milestone
8. Glysure Presents Successful Clinical Trial Results at ISICEM
9. Johnson & Johnson to Provide Webcast Presentation of XARELTO® (rivaroxaban) Phase 3 Clinical Data Presented at the American College of Cardiologys Annual Scientific Sessions
10. Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule
11. HeartWare Receives 54-Patient Allotment From FDA Under Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... March 30, 2017  Lannett Company, Inc. (NYSE: ... made a $25 million payment against its existing revolving ... combined with the $75 million payment we made earlier ... million in annualized cash interest expense, at current rates" ... Lannett.  "Our business is solid and we continue to ...
(Date:3/30/2017)... Revenue Prospects by Product Type (Metered Dose ... Geography Respiratory Inhalers - our new study reveals trends, ... market heading? If you are involved in this sector you must ... the potential revenues streams to 2027, assessing data, trends, opportunities and ... ...
(Date:3/30/2017)... 30, 2017  Purcell Julie & Lefkowitz LLP, a class ... a potential breach of fiduciary duty claim involving the board ... ). If you are a shareholder of ... this investigation, free of charge, please visit us at: ... http://pjlfirm.com/synergy-pharmaceuticals-inc/ ...
Breaking Medicine Technology:
(Date:3/30/2017)... ... March 30, 2017 , ... AudioEducator, ... conference “ Preventing Hospital Readmissions Through Discharge Planning ” with noted expert Sue ... ET. This conference discusses strategies to prevent readmissions in light of the most ...
(Date:3/29/2017)... ... 29, 2017 , ... During the last week of March, Chad Kawa, MD ... individuals in the local community. , Colon cancer is the second leading cause ... cancer while it is small, confined and easier to treat. If you are 50 ...
(Date:3/29/2017)... San Diego, CA (PRWEB) , ... March 29, 2017 , ... ... meningiomas(1,2), and up to 300,000 people each year develop other types of metastatic brain ... spread quickly throughout the brain(3). As efforts focus on finding more effective treatment options, ...
(Date:3/29/2017)... ... March 29, 2017 , ... Full Contact K9, an Atlanta-based ... Pet Protect Law that assists dog owners in creating legally-enforceable pet trusts for ... taking the natural next step to protect their new companion. Says Evan Dunbar, CEO ...
(Date:3/29/2017)... ... March 30, 2017 , ... CHARM CITY RUN WELCOMES MERCY MEDICAL ... that Mercy Medical Center will serve as the official title sponsor of the Baltimore ... June 25, 2017, thousands of women will walk or run the course around the ...
Breaking Medicine News(10 mins):